Literature DB >> 25283844

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.

E Ferretti1, C Tripodo2, G Pagnan1, C Guarnotta2, D Marimpietri1, M V Corrias1, D Ribatti3, S Zupo4, G Fraternali-Orcioni5, J L Ravetti5, V Pistoia1, A Corcione1.   

Abstract

Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation. In contrast, GC B cells did not signal to IL-31 in spite of IL-31R expression. GC B cells expressed predominantly the inhibitory short IL-31RA isoform, whereas FL cells expressed predominantly the long signaling isoform. Moreover, GC B cells lacked expression of other IL-31RA isoforms potentially involved in the signaling pathway. IL-31 protein expression was significantly higher in surface membrane than in cytosol of both FL and GC B cells. IL-31 was detected in plasma membrane microvesicles from both cell types but not released in soluble form in culture supernatants. IL-31 and IL-31RA expression was higher in lymph nodes from FL patients with grade IIIa compared with grade I/II, suggesting a paracrine and/or autocrine role of IL-31/IL-31RA complex in tumor progression through microvesicle shedding.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25283844     DOI: 10.1038/leu.2014.291

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

Review 1.  Mast cell signal transduction from the high-affinity IgE receptor.

Authors:  Reuben P Siraganian
Journal:  Curr Opin Immunol       Date:  2003-12       Impact factor: 7.486

2.  Correlation of IL-31 serum levels with severity of atopic dermatitis.

Authors:  Ulrike Raap; Katja Wichmann; Manuela Bruder; Sonja Ständer; Bettina Wedi; Alexander Kapp; Thomas Werfel
Journal:  J Allergy Clin Immunol       Date:  2008-08       Impact factor: 10.793

3.  Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway.

Authors:  S Thiel; I Behrmann; E Dittrich; L Muys; J Tavernier; J Wijdenes; P C Heinrich; L Graeve
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

4.  Interleukin (IL)-31 activates signal transducer and activator of transcription (STAT)-1, STAT-5 and extracellular signal-regulated kinase 1/2 and down-regulates IL-12p40 production in activated human macrophages.

Authors:  S Kasraie; M Niebuhr; T Werfel
Journal:  Allergy       Date:  2013-04-27       Impact factor: 13.146

Review 5.  Indolent lymphomas of mature B lymphocytes.

Authors:  Paul J Kurtin
Journal:  Hematol Oncol Clin North Am       Date:  2009-08       Impact factor: 3.722

6.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

Review 7.  Mechanisms of interleukin-1beta release.

Authors:  Claudia Eder
Journal:  Immunobiology       Date:  2009-02-27       Impact factor: 3.144

8.  Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Authors:  Jutta Horejs-Hoeck; Harald Schwarz; Sebastian Lamprecht; Elisabeth Maier; Stefan Hainzl; Maria Schmittner; Gernot Posselt; Angelika Stoecklinger; Thomas Hawranek; Albert Duschl
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

9.  Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation.

Authors:  Bryony Stott; Paul Lavender; Sarah Lehmann; Davide Pennino; Stephen Durham; Carsten B Schmidt-Weber
Journal:  J Allergy Clin Immunol       Date:  2013-05-18       Impact factor: 10.793

10.  Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression.

Authors:  Danilo Marimpietri; Andrea Petretto; Lizzia Raffaghello; Annalisa Pezzolo; Cristina Gagliani; Carlo Tacchetti; Pierluigi Mauri; Giovanni Melioli; Vito Pistoia
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

View more
  16 in total

1.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

2.  Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.

Authors:  F Morandi; D Marimpietri; A L Horenstein; M Bolzoni; D Toscani; F Costa; B Castella; A C Faini; M Massaia; V Pistoia; N Giuliani; F Malavasi
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

3.  Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.

Authors:  Alain H Rook; Kathryn A Rook; Daniel J Lewis
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).

Authors:  Michael T Werner; Qian Zhang; Mariusz A Wasik
Journal:  Cancers (Basel)       Date:  2017-10-16       Impact factor: 6.639

5.  Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.

Authors:  Fabio Morandi; Danilo Marimpietri; Alberto L Horenstein; Maria Valeria Corrias; Fabio Malavasi
Journal:  Oncoimmunology       Date:  2019-02-19       Impact factor: 8.110

Review 6.  IL-31, itch and hematological malignancies.

Authors:  Eleonora Di Salvo; Alessandro Allegra; Marco Casciaro; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2021-06-12

Review 7.  IL-33/IL-31 Axis: A Potential Inflammatory Pathway.

Authors:  Eleonora Di Salvo; Elvira Ventura-Spagnolo; Marco Casciaro; Michele Navarra; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2018-03-11       Impact factor: 4.711

8.  The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.

Authors:  Shiri Davidi; Ella Fremder; Tal Kan; Ziv Raviv; Michael Timaner; Nathan Karin; Dov Hershkovitz; Ami Arohneim; Yuval Shaked
Journal:  Oncotarget       Date:  2017-03-07

9.  Genetic Association of Interleukin-31 Gene Polymorphisms with Epithelial Ovarian Cancer in Chinese Population.

Authors:  Chenlu Liu; Yanyun Wang; Huizi Song; Qin Li; Yan Zhang; Peng Chen; Yaping Song; Min Su; Qin Huang; Mei Wang; Bin Zhou; Lin Zhang
Journal:  Dis Markers       Date:  2018-02-01       Impact factor: 3.434

10.  Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients.

Authors:  Elisa Ferretti; Stefan Hohaus; Arianna Di Napoli; Beatrice Belmonte; Annarosa Cuccaro; Elisa Cupelli; Eugenio Galli; Vittoria Rufini; Gino Tripodi; Giulio Fraternali-Orcioni; Vito Pistoia; Anna Corcione
Journal:  Oncotarget       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.